According to a multi-center clinical trial led by researchers at the Stanford University School of Medicine, a new type of immunotherapy seems to be safe for patients with blood cancer called non-Hodgkin’s lymphoma.
The therapy combines experimental antibodies developed by researchers at Stanford University and commercially available anti-cancer antibodies to rituximab. It referred Hu5F9-G4 experimental protein antibody blockade of CD47 , of CD47 suppressed immune attack against cancer cells. The combination of two antibodies is used to treat people with two types of Hodgkin bo'lmagan limfoma: diffuse large B- cell lymphoma and follicular lymphoma.
2010 yilda Stenford Ildiz Hujayra Biologiyasi va Regenerativ Tibbiyot Instituti direktori Irving Vaysman boshchiligidagi tadqiqotchilar deyarli barcha saraton hujayralari CD47 deb ataladigan oqsil bilan qoplanganini ko'rsatdilar. makrofaglarga.
Weissman and colleagues later developed an antibody called Hu5F9-G4 that blocks the CD47 protein and encourages macrophages to engulf cancer cells. Rituximab is an antibody that has been shown to amplify the positive ” eat me ” signal. The combination of rituximab and Hu5F-G4 has previously been shown to be effective against human cancer in animal models, but this is the first published result of clinical trials of the therapy in humans.
Sinovda ishtirok etgan 22 bemordan 11 bemorda klinik saraton kasalligi sezilarli darajada kamaygan va 8 bemorda saratonning barcha belgilari yo'q qilingan. Sinovdagi qolgan uchta bemor davolanishga javob bermadi va kasallikning kuchayishi tufayli vafot etdi. Tadqiqotchilar ishtirokchilarda faqat kichik nojo'ya ta'sirlar borligini kuzatishdi.
Dr. Saul A. Rosenberg , a lymphoma professor , said that such a potential new immunoterapiya is very exciting. This is the first time that an antibody that can activate macrophages to fight cancer is used, and it seems to be safe for use in humans.
https://medicalxpress.com/news/2018-10-anti-cd47-cancer-therapy-safe-small.html
